Κόσμος

AstraZeneca’s COVID-19 vaccine trial data

Health

On March 23, Reuters was more than a minute ahead with news that leading U.S. health agency Data Safety Monitoring Board has concerns that AstraZeneca may have included outdated information on its latest COVID-19 vaccine trial.

Market Impact

The news sent AstraZeneca shares down 2% in premarket trading.

Article Tags

Topics of Interest: Health

Type: Reuters News First

Sectors: Pharmaceuticals & Healthcare

Regions: North America

Win Types: Speed

Media Types: Text

Customer Impact: Major Global Story

Source link

Show More

Related Articles

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *

Back to top button
Close
Close